Emplicure AB today reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain
Emplicure today reported dosing in the first pharmacokinetic study with EMPLI03, intended for the treatment of moderate to severe pain. 12 healthy subjects were given a single dose of an oral buccal tablet and blood samples were collected for analysis of Buprenorphine. Safety and tolerability were followed, and the subjects could leave the clinic after completion of the study as planned. Top line data will be available in the beginning of 2023.
The Emplicure group is developing innovative consumer and pharmaceutical products based on its proprietary bioceramic technology platform, Emplior.
EMPLI03 is being developed as an oral buccal tablet with extended release properties intended for the treatment of moderate to severe pain. The formulation is also designed to limit the potential for manipulation of the tablet for abuse. Supported by its Translational Pharmaceutics® platform Quotient Sciences has established the GMP manufacturing process of EMPLI03 and performed this first pharmacokinetic study for Emplicure.
"We have achieved one of our milestones in the development of a Buprenorphine product for the treatment of moderate to severe pain. With properties that limit abuse, EMPLI03 may contribute to a safer medical treatment", said Håkan Engqvist, CEO of Emplicure.
Pain is a major health issue globally and, in the US, as many as 20% of the population is estimated to suffer from chronic pain and in need of long-term pain relief. Widespread moderate to severe pain is a problem that is associated with high costs for society and individual patients. Opioids are, and will continue to be, an important part of pain treatment.
For additional information, please contact
CEO Phone: +46 702 569 500 Email: email@example.com
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.
Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com
Emplicure AB (publ) today announced that the company has entered into an agreement with Erik Penser Bank ("Penser") whereby Penser will act as liquidity provider for the Emplicure share, starting 24 November 2022.
Emplicure AB (publ) has today entered into a loan agreement with a loan consortium through which the Company has taken up a loan in the amount of 9.0 MSEK. The loan consortium includes certain existing shareholders, including the board member Johan Wieslander. The purpose of the loan is to strengthen the Company's short-term working capital and to meet the requirement of going concern for the next twelve months.
Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in May 2023 is formed. The Nomination Committee consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to give preference for more shareholders.
Uppsala 2022-09-19 Emplicure AB (publ) announces today that the Company's Board of Directors has resolved to implement a holding company structure with operational subsidiaries. The purpose of the restructuring is to increase visibility and reinforce the Group's ability to focus on business and product development across various product areas, including nicotine and pharmaceuticals as well as other consumer product areas. As a direct consequence of the above, the Board of Directors has appointed Tomas Hammargren as CEO of the subsidiary Amplicon.